TORONTO, Oct. 13, 2020 (GLOBE NEWSWIRE) -- CB2 Insights (the “Company” or “CB2”) (CSE:CBII OTCQB:CBIIF), one of the largest integrative healthcare systems in the United States, is pleased to announce it will be participating in the Gravitas Technology and Diversified Investor Day taking place Thursday, October 15th, 2020 virtually.
CB2’s Chief Executive Officer, Pradyum Sekar, is scheduled to present on Thursday, October 15th at 3:00 PM EST. Mr. Sekar will also be fielding investor questions during the one-day virtual conference hosted by Gravitas Securities Inc. “I am looking forward to sharing our growth strategy with investors at the Gravitas Technology and Diversified Investor Day,” said Mr. Sekar. “With the recent acquisition of Texas-based Maverick County Medical serving over 10,300 patients, the Gravitas Technology and Diversified Investor Day is an ideal venue to communicate our progress to investors.”
This year’s Gravitas Technology and Diversified Investor Day will feature several leaders in Technology and Diversified industries and will be attended virtually by institutional and retail investors from North America and abroad. For additional details about the conference and Gravitas Securities Inc., please visit: www.gravitassecurities.com
Conference Details:
| Event: | Gravitas Technology and Diversified Investor Day (virtual) |
| Format: | Presentation |
| Date: | Thursday, October 15th |
| Time: | 9:30 AM – 4:15 PM EST |
| Registration: | Link |
CB2 Insights
CB2 Insights (CSE:CBII OTCQB:CBIIF) is a healthcare services and technology company, working to positively impact patient health outcomes. The Companies mission to improve the lives of patients through the prevention and treatment of health conditions and using proprietary technology to monitor, assess, and generate insights to help improve patient outcomes. The Company owns and operates a proprietary virtual telehealth platform, and a network of over 30 medical clinics across 13 states in the US, providing integrative, primary, and urgent care services to over 110,000 patients annually.
The Company has created works primarily to roster and treat patients seeking traditional and alternative treatments due to the ineffectiveness of conventional medicine, inability to find support through their existing care network, or in some cases, inability to access a primary care network. The Company offers both primary care via a traditional insurable services model and a disruptive low-cost subscription based urgent care offering for patients seeking immediate need to a healthcare provider via telehealth.
The Company differentiates itself by being one of the largest integrative medical practices in the US that owns its own proprietary technology, data analytical assets, and clinical research expertise to support new market expansion, market access, data collection and analysis and drug discovery.
The Company operates a proprietary electronic health record platform Sail (“Sail”) to document, treat, monitor, and report on patient health outcomes. Developed in 2015, Sail is used internally across all of the Company’s clinical operations. Sail features a robust telemedicine platform that the Company uses to provide care to its National patient base. To support patient care and positive health outcomes, the Company is also focused on advancing safety and efficacy research surrounding alternative health treatments by monitoring and assessing Real-World Data (RWD) and providing Real-World Evidence (RWE) through our proprietary technology, data analytics, and a full service contract research organization.
For further information, please contact:
| Investor Relations Jonathan L. Robinson CFA Oak Hill Financial jrobinson@oakhillfinancial.ca 416-669-1001 |
Forward Looking Statements
Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in CB2’s filings with Canadian securities regulators. When used in this news release, words such as "will, could, plan, estimate, expect, intend, may, potential, believe, should," and similar expressions, are forward-looking statements.
Forward-looking statements may include, without limitation, statements regarding the Company’s unaudited financial results and projected growth.
Although CB2 has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; investing in target companies or projects which have limited or no operating history and are subject to inconsistent legislation and regulation; change in laws; reliance on management; requirements for additional financing; competition; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and recreational-use marijuana industry and; regulatory or political change.
There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.
Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. CB2 disclaims any intention or obligation to update or revise such information, except as required by applicable law, and CB2 does not assume any liability for disclosure relating to any other company mentioned herein.
No securities regulator or exchange has reviewed, approved, disapproved, or accepts responsibility for the content of this news release.